ABIO ARCA biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABIO

Price (delayed)

$1.9

Market cap

$27.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.37

Enterprise value

-$10.88M

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically ...

Highlights
The company's quick ratio has surged by 71% YoY and by 55% QoQ
ARCA biopharma's EPS has soared by 63% YoY and by 14% from the previous quarter
The company's equity fell by 11% YoY and by 3.2% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.arcabiopharma.com
Peers: CYTK PTN MDT UTHR

Key stats

What are the main financial stats of ABIO
Market
Shares outstanding
14.41M
Market cap
$27.38M
Enterprise value
-$10.88M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.72
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$5.42M
EBITDA
-$5.31M
Free cash flow
-$5.45M
Per share
EPS
-$0.37
Free cash flow per share
-$0.38
Book value per share
$2.63
Revenue per share
$0
TBVPS
$2.72
Balance sheet
Total assets
$39.18M
Total liabilities
$1.22M
Debt
$224,000
Equity
$37.97M
Working capital
$37.9M
Liquidity
Debt to equity
0.01
Current ratio
39.21
Quick ratio
38.8
Net debt/EBITDA
7.21
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-13.1%
Return on equity
-13.6%
Return on invested capital
N/A
Return on capital employed
-14.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABIO stock price

How has the ARCA biopharma stock price performed over time
Intraday
0.09%
1 week
1.6%
1 month
1.6%
1 year
-7.77%
YTD
-19.83%
QTD
-5.47%

Financial performance

How have ARCA biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$7.25M
Net income
-$5.42M
Gross margin
N/A
Net margin
N/A
ARCA biopharma's net income has surged by 62% YoY and by 14% QoQ
ABIO's operating income has soared by 51% year-on-year and by 8% since the previous quarter

Growth

What is ARCA biopharma's growth rate over time

Valuation

What is ARCA biopharma stock price valuation
P/E
N/A
P/B
0.72
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ARCA biopharma's EPS has soared by 63% YoY and by 14% from the previous quarter
The company's equity fell by 11% YoY and by 3.2% QoQ
ABIO's price to book (P/B) is 10% lower than its 5-year quarterly average of 0.8 and 10% lower than its last 4 quarters average of 0.8

Efficiency

How efficient is ARCA biopharma business performance
The return on equity has surged by 56% year-on-year and by 12% since the previous quarter
ARCA biopharma's return on assets has surged by 55% YoY and by 11% QoQ

Dividends

What is ABIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABIO.

Financial health

How did ARCA biopharma financials performed over time
The company's quick ratio has surged by 71% YoY and by 55% QoQ
The company's current ratio has surged by 70% YoY and by 54% QoQ
The company's debt is 99% lower than its equity
The company's debt fell by 26% YoY and by 8% QoQ
The company's equity fell by 11% YoY and by 3.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.